Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 in Subjects With Advanced or Metastatic Solid Tumors

NCT05383898 is registered in ClinicalTrials.gov with InventisBio Co., Ltd as lead sponsor.

NCT NCT05383898
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05383898 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 in Subjects With Advanced or Metastatic Solid Tumors
Lead sponsor
InventisBio Co., Ltd
Phase
Phase 1/2
Overall status
Completed
Start date
March 16, 2021
Completion date
May 17, 2024
Enrollment
225 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc